Clinical Trials Directory

Trials / Completed

CompletedNCT00209456

Dopamine Transporter Scintigraphy Imaging (DAT-Imaging) in Patients With Lewy Body Dementia

GEHC Has Decided Not to Provide This Detail But Will Rely on the Brief Title

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
326 (planned)
Sponsor
GE Healthcare · Industry
Sex
All
Age
55 Years – 90 Years
Healthy volunteers
Not accepted

Summary

The study is designed to determine the diagnostic efficacy of the visual assessment of SPECT scans in differentiating between probable dementia with Lewy Bodies (DLB) and non-DLB dementia subjects determined by the clinical diagnosis of an independent expert consensus panel used as the standard of truth.

Detailed description

GEHC had decided notto provide this detail

Conditions

Interventions

TypeNameDescription
DRUGDatSCAN

Timeline

Start date
2003-11-01
First posted
2005-09-21
Last updated
2007-05-16

Locations

1 site across 1 country: Germany

Source: ClinicalTrials.gov record NCT00209456. Inclusion in this directory is not an endorsement.

Dopamine Transporter Scintigraphy Imaging (DAT-Imaging) in Patients With Lewy Body Dementia (NCT00209456) · Clinical Trials Directory